文献速递肾移植

肾移植受者中加巴喷丁类、阿片类与苯二氮䓬类药物的同时处方情况

Gabapentin, Concomitant Prescription of Opioids, and Benzodiazepines among Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-01-01

基于美国肾脏数据系统/联邦医疗保险索赔数据库,纳入2006至2017年参加Medicare Part D的成人肾移植受者,分析移植后加巴喷丁类、阿片类与苯二氮䓬类的同时处方情况及其与移植后死亡率的关联。结果显示加巴喷丁类处方率在研究期间上升70%,且与阿片类或苯二氮䓬类联用与更高的移植后死亡风险相关。

要点

  • 63,359例受者中13%在移植后1年内至少配取一次加巴喷丁类处方
  • 加巴喷丁类处方率从2006年10%升至2017年16%,增幅70%
  • 加巴喷丁类单药及与阿片类或苯二氮䓬类联用均与移植后死亡风险升高相关

核心结论

  • 肾移植受者中加巴喷丁类与苯二氮䓬类及阿片类的同时处方随时间增加,加巴喷丁类处方与移植后死亡风险升高相关,联用阿片类或苯二氮䓬类时风险更高。

研究设计与样本

  • 使用美国肾脏数据系统/联邦医疗保险索赔数据库,识别2006至2017年参加Medicare Part D的成人肾移植受者,采用Cox回归并纳入逆概率加权调整混杂因素。

主要发现

  • 63,359例合格受者中,13%在肾移植后1年内至少配取一次加巴喷丁类处方。
  • 加巴喷丁类处方患病率在研究期间增加70%(2017年16% vs 2006年10%)。
  • 与未使用者相比,加巴喷丁类使用者更可能患糖尿病(55% vs 37%)和肥胖(46% vs 34%)。
  • 8,509例有加巴喷丁类处方的受者中,45%同时处方阿片类,7%同时处方苯二氮䓬类,3%同时处方阿片类和苯二氮䓬类。
  • 与无研究药物处方相比,加巴喷丁类单药治疗(aHR=1.25;95%CI 1.16至1.32)、加巴喷丁类联合阿片类(aHR=1.49;95%CI 1.39至1.60)、加巴喷丁类联合苯二氮䓬类(aHR=1.46;95%CI 1.03至2.08)及三者同时处方(aHR=1.88;95%CI 1.18至2.98)均与移植后死亡风险升高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gabapentinoids, commonly used for treating neuropathic pain, may be misused and coprescribed with opioid and benzodiazepine, increasing the risk of mortality and dependency among kidney transplant recipients. METHODS: We identified adult kidney transplant recipients who enrolled in Medicare Part D in 2006-2017 using the United States Renal Data System/Medicare claims database. We characterized recipients' post-transplant concomitant prescription of gabapentinoids, opioids, and benzodiazepine stratified by transplant year and recipient factors (age, sex, race, and diabetes). We investigated whether concomitant prescriptions were associated with postkidney transplant mortality using Cox regression. Models incorporated inverse probability weighting to adjust for confounders. RESULTS: Among 63,359 eligible recipients, 13% of recipients filled at least one gabapentinoid prescription within 1 year after kidney transplant. The prevalence of gabapentinoid prescriptions increased by 70% over the study period (16% in 2017 versus 10% in 2006). Compared with nonusers, gabapentinoids users were more likely to have diabetes (55% versus 37%) and obesity (46% versus 34%). Of the 8509 recipients with gabapentinoid prescriptions, 45% were coprescribed opioids, 7% were coprescribed benzodiazepines, and 3% were coprescribed both opioids and benzodiazepines. Compared with no study prescriptions, gabapentinoid monotherapy (adjusted hazard ratio [aHR]=1.25; 95% confidence interval [CI], 1.16 to 1.32) and combination therapy (gabapentinoids and opioids [aHR=1.49; 95% CI, 1.39 to 1.60], gabapentinoids and benzodiazepines [aHR=1.46; 95% CI, 1.03 to 2.08], and coprescribing all three [aHR=1.88; 95% CI, 1.18 to 2.98]) were all associated with a higher risk of postkidney transplant mortality. CONCLUSIONS: Gabapentinoid coprescription with both benzodiazepines and opioids among kidney transplant recipients increased over time. Kidney transplant recipients prescribed gabapentinoids had a higher risk of post-transplant mortality, and the risk was higher with opioids or benzodiazepine coprescription.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Ahn JB, Bae S, et al. Gabapentin, Concomitant Prescription of Opioids, and Benzodiazepines among Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2023. PMID: 36719161. doi:10.2215/CJN.0000000000000019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。